References
[1] Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the
World Health Organization classification of myeloid neoplasms and acute
leukemia. Blood. 2016;127(20):2391–405.
[2] Li Y, Sun V, Sun W, Pawlowska A. Blastic Plasmacytoid Dendritic
Cell Neoplasm in Children. Hematol Oncol Clin North Am. 2020. 34(3):
601-612.
[3] Sapienza MR, Pileri A, Derenzini E, et al. Blastic Plasmacytoid
Dendritic Cell Neoplasm: State of the Art and Prospects. Cancers
(Basel). 2019. 11(5).
[4] Laribi K, Denizon N, Besancon A, et al. Blastic plasmacytoid
dendritic cell neoplasm: from origin of the cell to targeted therapies.
Biol Blood Marrow Transplant. 2016;22(8):1357–67.
[5] Tokuda K, Eguchi-Ishimae M, Yagi C, et al. CLTC-ALK fusion as a
primary event in congenital blastic plasmacytoid dendritic cell
neoplasm. Genes Chromosomes Cancer. 2014. 53(1): 78-89.
[6] Chen C, Liu Y, Rappaport AR, et al. MLL3 is a haploinsufficient
7q tumor suppressor in acute myeloid leukemia. Cancer Cell. 2014. 25(5):
652-65.
[7] Lee J, Kim DH, Lee S, et al. A tumor suppressive coactivator
complex of p53 containing ASC-2 and histone H3-lysine-4
methyltransferase MLL3 or its paralogue MLL4. Proc Natl Acad Sci U S A.
2009. 106(21): 8513-8.
[8] Toya T, Nishimoto N, Koya J, et al. The first case of blastic
plasmacytoid dendritic cell neoplasm with MLL-ENL rearrangement. Leuk
Res. 2012. 36(1): 117-8.
[9] Yang N, Huh J, Chung WS, Cho MS, Ryu KH, Chung HS. KMT2A
(MLL)-MLLT1 rearrangement in blastic plasmacytoid dendritic cell
neoplasm. Cancer Genet. 2015. 208(9): 464-7.
[10] Liao C, Hu NX, Song H, et al. Pediatric blastic plasmacytoid
dendritic cell neoplasm: report of four cases and review of literature.
Int J Hematol. 2021. 113(5): 751-759.